Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Myokardia Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned across 3 examiners and 3 art units, so no broader concentration is identified in the reported docket.
SCHMITT, MICHAEL J is the busiest identified examiner, with 1 pending matter. Counsel can focus on the individual application records while maintaining a consistent approach to biotechnology claim scope.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
| ROSENTHAL, ANDREW S | 1 | 51.9% | +39.0% |
| NGUYEN, JOHN P | 1 | 43.9% | +41.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001896 | TREATMENT OF ATRIAL DYSFUNCTION | NGUYEN, JOHN P | 3d overdue |
| 19288391 | TREATMENT OF HCM WITH PYRIMIDINEDIONE COMPOUNDS | SCHMITT, MICHAEL J | — |
| 19001910 | TREATMENT OF SYSTOLIC DYSFUNCTION | ROSENTHAL, ANDREW S | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1613 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19288391 | TREATMENT OF HCM WITH PYRIMIDINEDIONE COMPOUNDS | SCHMITT, MICHAEL J | 1629 | §103Other | Final Rejection | — | Pending | Aug 01, 2025 |
| 19001910 | TREATMENT OF SYSTOLIC DYSFUNCTION | ROSENTHAL, ANDREW S | 1613 | §103 | Non-Final OA | — | Pending | Dec 26, 2024 |
| 18001896 | TREATMENT OF ATRIAL DYSFUNCTION | NGUYEN, JOHN P | 1619 | §103Other | Final Rejection | 3d overdue | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMyokardia Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Michael J Schmitt has the most, with 1 of Myokardia Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
